Abstract
Three different antibodies against a human TNF receptor (htr-1, htr-5, and htr-9) have been examined for their binding pattern to U937 cells and ability to mimic TNF-alpha activity in U937 cells, Fs4 fibroblasts, and human endothelial cells. Flow cytometric analysis revealed that htr-5 and htr-9 bound specifically to a TNF receptor on U937 cells that could be blocked by pretreatment with rTNF-alpha. Pretreatment of U937 cells with rTNF-beta blocked the binding of htr-9, but to a lesser extent htr-5 binding. Pretreatment with htr-5 inhibited the binding of htr-9 to U937 cells while pretreatment with htr-9 did not inhibit htr-5 binding. These results indicate that htr-5 and htr-9 recognize distinct but overlapping epitopes of a human TNF receptor on U937 cells and that htr-5 may be close to a TNF-alpha-specific domain of the binding site. Pretreatment with htr-5 or htr-9 only minimally reduced binding of BrTNF-alpha to U937 cells; however, these antibodies were much more effective in inhibiting BrTNF-alpha binding to HL-60 cells. Furthermore, it was found that htr-1 and htr-9, but not htr-5, had TNF-alpha activity on U937 cells, Fs4 fibroblasts, and endothelial cells and that the TNF-alpha activity induced by htr-9 was completely inhibited by htr-5. However, the cytotoxic activity of TNF-alpha was only partially inhibited by htr-5 on U937 cells while htr-5 had no effect on TNF-alpha activity on Fs4 cells. The data suggest that a common epitope is involved in inducing TNF-alpha activity in three different cell systems.
MeSH Terms
Antibodies, Monoclonal/immunology
Binding, Competitive
Cell Line
Cell Survival/drug effects
Epitopes/immunology
Flow Cytometry
Humans
Lymphotoxin-alpha/pharmacology
Receptors, Cell Surface/immunology
Receptors, Tumor Necrosis Factor
Recombinant Proteins/pharmacology
Tumor Necrosis Factor-alpha/pharmacology
Chemicals
Antibodies, Monoclonal
Epitopes
Lymphotoxin-alpha
Receptors, Cell Surface
Receptors, Tumor Necrosis Factor
Recombinant Proteins
Tumor Necrosis Factor-alpha
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Espevik T
Institute of Cancer Research, University of Trondheim, Norway.
Brockhaus M
Loetscher H
Nonstad U
Shalaby R
References (19)
19 references, click to expand
-
Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity.
Nature. 1984 Dec 20-1985 Jan 2;312(5996):721-4
PMID: 6334807
-
Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin.
Nature. 1984 Dec 20-1985 Jan 2;312(5996):724-9
PMID: 6392892
-
Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha.
J Exp Med. 1987 Oct 1;166(4):991-8
PMID: 3498791
-
Modulation of endothelial cell hemostatic properties by tumor necrosis factor.
J Exp Med. 1986 Mar 1;163(3):740-5
PMID: 3753996
-
Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors.
J Immunol. 1985 Sep;135(3):2069-73
PMID: 3926894
-
Characterization of human tumor necrosis factor produced by peripheral blood monocytes and its separation from lymphotoxin.
Int J Cancer. 1985 Jul 15;36(1):69-73
PMID: 3874835
-
Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor.
Proc Natl Acad Sci U S A. 1985 Dec;82(24):8667-71
PMID: 3866246
-
Factors influencing endothelial cell proliferation in vitro.
J Cell Physiol. 1978 Aug;96(2):203-13
PMID: 670305
-
Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors.
J Exp Med. 1986 Mar 1;163(3):632-43
PMID: 3512757
-
Effect of tumor necrosis factor alpha on mitogen-activated human B cells.
J Exp Med. 1987 Sep 1;166(3):786-91
PMID: 3040886
-
Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon.
Nature. 1985 Dec 19-1986 Jan 1;318(6047):665-7
PMID: 3001529
-
A high molecular weight component of the human tumor necrosis factor receptor is associated with cytotoxicity.
Proc Natl Acad Sci U S A. 1987 May;84(10):3293-7
PMID: 3033642
-
Independent regulation of tumor necrosis factor and lymphotoxin production by human peripheral blood lymphocytes.
J Exp Med. 1987 Jun 1;165(6):1581-94
PMID: 3108447
-
A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor.
J Exp Med. 1989 May 1;169(5):1747-56
PMID: 2469768
-
Alteration of the phospholipid composition of Escherichia coli through genetic manipulation.
J Biol Chem. 1989 Sep 5;264(25):14972-7
PMID: 2549045
-
Cytokine regulation of interleukin 6 production by human endothelial cells.
Cell Immunol. 1989 Jul;121(2):372-82
PMID: 2500254
-
Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1.
J Immunol. 1988 Apr 1;140(7):2312-6
PMID: 3280680
-
Immunoaffinity isolation of membrane antigens with biotinylated monoclonal antibodies and immobilized streptavidin matrices.
J Immunol Methods. 1984 Oct 12;73(1):83-95
PMID: 6386987
-
Tumor necrosis factors alpha and beta differ in their capacities to generate interleukin 1 release from human endothelial cells.
J Immunol. 1987 Sep 15;139(6):1891-5
PMID: 3497981